Meetings & Events

Hypertriglyceridemia and Cardiovascular Disease: To Treat or Not to Treat

July 21, 2020

Session Description: This session will describe the efficacy and safety of lowering triglycerides in statin-treated patients with and without CVD, including patients with type 2 diabetes.

Faculty: Savitha Subramanian, MD
University of Washington

Learning Objectives:

  1. Define Hypertriglyceridemia and explain evidence for the role of triglyceride rich lipoproteins in the development of atherosclerosis.
  2. Describe efficacy and safety in CVD outcome trials of triglyceride lowering drugs, including omega-3 fatty acids.
  3. Identify which patients might benefit from the addition of omega-3 fatty acids or fibrates to statin therapy.
  4. Discuss benefits and risks of omega-3 fatty acids in patients with type 2 diabetes.

Return to the full CEU program.

Last Updated:
ESAP 2022

Test Your Knowledge

Test your knowledge in everyday practice with Endocrine Self-Assessment Program (ESAP™), the premier self-assessment tool for all areas of endocrinology, diabetes, and metabolism. This year’s edition features 120 newly published clinical cases and questions, including a variety of common and rare conditions. Certified for 40.0 AMA PRA Category 1 Credits™ and 40.0 ABIM MOC Points, this product includes access to interactive online modules as well as a printed book to guide your study.

Test your knowledge in everyday practice with Endocrine Self-Assessment Program (ESAP™), the premier self-assessment tool for all areas of endocrinology, diabetes, and metabolism. This year’s edition features 120 newly published clinical cases and questions, including a variety of common and rare conditions. Certified for 40.0 AMA PRA Category 1 Credits™ and 40.0 ABIM MOC Points, this product includes access to interactive online modules as well as a printed book to guide your study.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.